| Titre : | The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review (2019) |
| Auteurs : | Christelle de la Fouchardiere |
| Type de document : | Article |
| Dans : | Bulletin du cancer (Vol. 106, n° 9, Septembre 2019) |
| Article en page(s) : | p. 812-819 |
| Langues: | Anglais |
| Descripteurs : |
HE Vinci Biologie moléculaire ; Thérapie moléculaire ciblée ; Tumeurs de la thyroïde |
| Résumé : | Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of cancer-related death. Multidisciplinary discussions can assess the role and the nature of local treatments, but also determine the optimal timing for first-line antiangiogenic therapy as some of these patients can be followed for several months or years without any treatment. In this review, we will examine the definition of RAIR-DTC, the different treatment options and finally some of the most recent cancer research breakthroughs for RAIR-DTC. |
| Disponible en ligne : | Non |
Exemplaires (1)
| Cote | Support | Localisation | Section | Disponibilité |
|---|---|---|---|---|
| Bulletin du cancer. Vol. 106, n° 9 (Septembre 2019) | Périodique papier | Woluwe | Espace revues | Consultation sur place uniquement Exclu du prêt |
